These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33942901)

  • 21. Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.
    Nai A; Rubio A; Campanella A; Gourbeyre O; Artuso I; Bordini J; Gineste A; Latour C; Besson-Fournier C; Lin HY; Coppin H; Roth MP; Camaschella C; Silvestri L; Meynard D
    Blood; 2016 May; 127(19):2327-36. PubMed ID: 26755707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis.
    Finberg KE; Whittlesey RL; Fleming MD; Andrews NC
    Blood; 2010 May; 115(18):3817-26. PubMed ID: 20200349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
    Olivera J; Zhang V; Nemeth E; Ganz T
    Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
    Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
    Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A; Gillard S; Spino M; Connelly J; Tricta F
    Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
    Camaschella C; Nai A
    Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
    Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
    Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepcidin independent iron recycling in a mouse model of β-thalassaemia intermedia.
    Frazer DM; Wilkins SJ; Mirciov CS; Dunn LA; Anderson GJ
    Br J Haematol; 2016 Oct; 175(2):308-317. PubMed ID: 27410488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matriptase-2 and Hemojuvelin in Hepcidin Regulation: In Vivo Immunoblot Studies in
    Krijt J; Frýdlová J; Gurieva I; Přikryl P; Báječný M; Steinbicker AU; Vokurka M; Truksa J
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
    Finberg KE; Whittlesey RL; Andrews NC
    Blood; 2011 Apr; 117(17):4590-9. PubMed ID: 21355094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepcidin downregulation by repeated bleeding is not mediated by soluble hemojuvelin.
    Krijt J; Fujikura Y; Sefc L; Vokurka M; Hlobenová T; Necas E
    Physiol Res; 2010; 59(1):53-59. PubMed ID: 19249912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis.
    Gutschow P; Schmidt PJ; Han H; Ostland V; Bartnikas TB; Pettiglio MA; Herrera C; Butler JS; Nemeth E; Ganz T; Fleming MD; Westerman M
    Haematologica; 2015 Feb; 100(2):167-77. PubMed ID: 25425686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
    Casu C; Oikonomidou PR; Chen H; Nandi V; Ginzburg Y; Prasad P; Fleming RE; Shah YM; Valore EV; Nemeth E; Ganz T; MacDonald B; Rivella S
    Blood; 2016 Jul; 128(2):265-76. PubMed ID: 27154187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hfe and Hjv exhibit overlapping functions for iron signaling to hepcidin.
    Kent P; Wilkinson N; Constante M; Fillebeen C; Gkouvatsos K; Wagner J; Buffler M; Becker C; Schümann K; Santos MM; Pantopoulos K
    J Mol Med (Berl); 2015 May; 93(5):489-98. PubMed ID: 25609138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice.
    Nai A; Pellegrino RM; Rausa M; Pagani A; Boero M; Silvestri L; Saglio G; Roetto A; Camaschella C
    Haematologica; 2014 Jun; 99(6):1016-21. PubMed ID: 24658816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.
    De Franceschi L; Daraio F; Filippini A; Carturan S; Muchitsch EM; Roetto A; Camaschella C
    Haematologica; 2006 Oct; 91(10):1336-42. PubMed ID: 17018382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.
    Botzenhardt S; Felisi M; Bonifazi D; Del Vecchio GC; Putti MC; Kattamis A; Ceci A; Wong ICK; Neubert A;
    Haematologica; 2018 Jan; 103(1):e1-e4. PubMed ID: 29079595
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.